This site uses cookies to improve your browsing experience. By continuing to browse this site you are agreeing to our use of cookies. For further information, please refer to Privacy Policy.
Ever-Supreme's new drug CAR001 has completed Phase I safety validation and has initiated Phase IIa, targeting the global solid tumor market.
Ever-Supreme's new drug CAR001 has successfully passed the review of the Phase I Clinical Trial Safety Monitoring Committee (SMC), completed the first phase of dose escalation and safety assessment, and officially launched the Phase IIa clinical trial. This will further expand the validation of efficacy and lay the foundation for future international licensing, multi-country and multi-center clinical trials and global market layout. At the same time, it will also actively seek international pharmaceutical companies for licensing cooperation and joint development opportunities to accelerate the clinical layout of CAR001 in the global solid tumor cell therapy market and provide more innovative treatment options for cancer patients.
